This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Birkett, A. Articles by Nardin, E. Search for Related Content PubMed PubMed Citation Articles by Birkett, A. Articles by Nardin, E.

 Previous Article  |  Next Article 

Infection and Immunity, December 2002, p. 6860-6870, Vol. 70, No. 12
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.12.6860-6870.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts

A. Birkett,¹ K. Lyons,¹ A. Schmidt,¹ D. Boyd,¹ G. A. Oliveira,² A. Siddique,² R. Nussenzweig,² J. M. Calvo-Calle,² and E. Nardin^2*

Apovia Inc., San Diego, California 92121,¹ Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York 10010²

Received 5 June 2002/ Returned for modification 13 July 2002/ Accepted 24 August 2002

Despite extensive public health efforts, there are presently 200 to 400 million malaria infections and 1 to 2 million deaths each year due to the Plasmodium parasite. A prime target for malaria vaccine development is the circumsporozoite (CS) protein, which is expressed on the extracellular sporozoite and the intracellular hepatic stages of the parasite. Previous studies in rodent malaria models have shown that CS repeat B-cell epitopes expressed in a recombinant hepatitis B virus core (HBc) protein can elicit protective immunity. To design a vaccine for human use, a series of recombinant HBc proteins containing epitopes of Plasmodium falciparum CS protein were assayed for immunogenicity in mice [A. Birkett, B. Thornton, D. Milich, G. A. Oliveira, A. Siddique, R. Nussenzweig, J. M. Calvo-Calle, and E. H. Nardin, abstract from the 50th Annual Meeting of the American Society of Tropical Medicine and Hygiene 2001, Am. J. Trop. Med. Hyg. 65(Suppl. 3):258, 2001; D. R. Milich, J. Hughes, J. Jones, M. Sallberg, and T. R. Phillips, Vaccine 20:771-788, 2001]. The present paper summarizes preclinical analyses of the optimal P. falciparum HBc vaccine candidate, termed ICC-1132, which contains T- and B-cell epitopes from the repeat region and a universal T-cell epitope from the C terminus of the CS protein. The vaccine was highly immunogenic in mice and in Macaca fascicularis (cynomolgus) monkeys. When formulated in adjuvants suitable for human use, the vaccine elicited antisporozoite antibody titers that were logs higher than those obtained in previous studies. Human malaria-specific CD4⁺-T-cell clones and T cells of ICC-1132-immunized mice specifically recognized malaria T-cell epitopes contained in the vaccine. In addition to inducing strong malaria-specific immune responses in naïve hosts, ICC-1132 elicited potent anamnestic antibody responses in mice primed with P. falciparum sporozoites, suggesting potential efficacy in enhancing the sporozoite-primed immune responses of individuals living in areas where malaria is endemic.

---

* Corresponding author. Mailing address: New York University School of Medicine, Department of Medical and Molecular Parasitology, 341 East 25th St., New York, NY 10010. Phone: (212) 263-6819. Fax: (212) 263-8116. E-mail: nardie01{at}popmail.med.nyu.edu.

Editor: W. A. Petri, Jr.

---

Infection and Immunity, December 2002, p. 6860-6870, Vol. 70, No. 12
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.12.6860-6870.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Hutchings, C. L., Birkett, A. J., Moore, A. C., Hill, A. V. S. (2007). Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. Infect. Immun. 75: 5819-5826 [Abstract] [Full Text]  
• ANDREWS, L., ANDERSEN, R. F., WEBSTER, D., DUNACHIE, S., WALTHER, R. M., BEJON, P., HUNT-COOKE, A., BERGSON, G., SANDERSON, F., HILL, A. V. S., GILBERT, S. C. (2005). QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. Am J Trop Med Hyg 73: 191-198 [Abstract] [Full Text]  
• Oliveira, G. A., Wetzel, K., Calvo-Calle, J. M., Nussenzweig, R., Schmidt, A., Birkett, A., Dubovsky, F., Tierney, E., Gleiter, C. H., Boehmer, G., Luty, A. J. F., Ramharter, M., Thornton, G. B., Kremsner, P. G., Nardin, E. H. (2005). Safety and Enhanced Immunogenicity of a Hepatitis B Core Particle Plasmodium falciparum Malaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial. Infect. Immun. 73: 3587-3597 [Abstract] [Full Text]  
• Nardin, E. H., Oliveira, G. A., Calvo-Calle, J. M., Wetzel, K., Maier, C., Birkett, A. J., Sarpotdar, P., Corado, M. L., Thornton, G. B., Schmidt, A. (2004). Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes. Infect. Immun. 72: 6519-6527 [Abstract] [Full Text]  
• BALLOU, W. R., AREVALO-HERRERA, M., CARUCCI, D., RICHIE, T. L., CORRADIN, G., DIGGS, C., DRUILHE, P., GIERSING, B. K., SAUL, A., HEPPNER, D. G., KESTER, K. E., LANAR, D. E., LYON, J., HILL, A. V. S., PAN, W., COHEN, J. D. (2004). UPDATE ON THE CLINICAL DEVELOPMENT OF CANDIDATE MALARIA VACCINES. Am J Trop Med Hyg 71: 239-247 [Abstract] [Full Text]